XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million.

The rally follows the company's announcement that its innovative drug, Xuan Yuening, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The successful NRDL negotiation is expected to enhance the affordability and accessibility of Xuan Yuening for patients, driving market expansion and sales growth, which will positively impact the company's long-term development.

Additionally, XUANZHUBIO-B has secured approvals for two oncology products this year, marking a critical milestone in its innovation-driven strategy. Piroxiclib, targeting differentiated indications in breast cancer, and Diloac, with high intracranial penetration and an IC-ORR exceeding 91%, address unmet needs in brain metastasis treatment. Together with Anaprazole Sodium, these drugs form a "troika" commercialization framework, laying a solid foundation for the company's sustained growth.